Results 361 to 370 of about 98,962 (385)

European Biopharmaceutical Culture [PDF]

Nature Biotechnology, 1990
Article synthese abordant le cote economique de l'utilisation du genie genetique pour la production de molecules recombinantes, par les industries biopharmaceutiques ...
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Fragmentation in the biopharmaceutical industry

Drug Discovery Today, 2017
The large number of biopharmaceutical mergers and acquisitions (M&A) that occurred over the past decade has generated questions about whether the industry is consolidating around too-few players, negatively impacting both the number of medicines developed and overall innovation.
Andrew D. Goldsmith, Francisco E. Varela
openaire   +3 more sources

Sorption Promotors in Biopharmaceutics

Angewandte Chemie International Edition in English, 1969
AbstractThe absorption of drugs depends on the physico‐chemical properties of the constituent substances. Drugs that are absorbed only with difficulty or only slowly, or even not at all, can be made to penetrate into the skin and the mucous membrane (penetration) or to pass through them (permeation) with the aid of “sorption promotors”.
openaire   +3 more sources

Biopharmaceutical evaluation of ‘Osmosin’

Current Medical Research and Opinion, 1983
'Osmosin' is an osmotically-controlled oral drug delivery system which presents a saturated solution of sodium indomethacin trihydrate (105.4 mg), equivalent to 85 mg indomethacin, to the gastro-intestinal tract at a constant rate of 7 mg per hour, with a release time of 10 to 12 hours.
openaire   +3 more sources

Immunogenicity of Biopharmaceuticals

2008
Immune Reactions Towards Biopharmaceuticals - a General, Mechanistic Overview.- Clinical Aspects of Immunogenicity to Biopharmaceuticals.- Assessment of Unwanted Immunogenicity.- Models for Prediction of Immunogenicity.- Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars.- Case Study: Immunogenicity of rhEPO.
Eva Horn Møller, Marco van de Weert
openaire   +2 more sources

Pharmacokinetics and Biopharmaceutics

1994
Besides the stabilization of unstable drugs, the modification of the pharmacokinetic and biopharmaceutical properties of a drug is the most significant effect of CD complexation.
Jozsef Szejtli, Karl-Heinz Frömming
openaire   +2 more sources

Multispecific drugs herald a new era of biopharmaceutical innovation

Nature, 2020
R. Deshaies
semanticscholar   +1 more source

Crystallography and Biopharmaceuticals

2015
Biopharmaceuticals generally describe drugs synthesized by biotechnology rather than chemistry, and are normally macromolecules such as proteins (vaccines, antibodies, hormones) or nucleic acids (RNA, DNA), but could also include synthetic biology ambitions such as designed therapeutic microorganisms.
openaire   +2 more sources

Second-generation biopharmaceuticals

European Journal of Pharmaceutics and Biopharmaceutics, 2004
The majority of first generation biopharmaceuticals are unengineered murine monoclonal antibodies or simple replacement proteins displaying an identical amino acid sequence to a native human protein. While some such products continue to be approved, an increasing number of modern biopharmaceuticals are engineered, second-generation products ...
openaire   +2 more sources

Purification of the Biopharmaceutical

2004
From the harvested production, the expressed biopharmaceutical needs to be purified in sufficient quantity to produce the bulk active pharmaceutical ingredient (API). Regardless of the type of production system used or its scale, the products will be purified using procedures common to either protein or DNA molecules.
openaire   +2 more sources